Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.77 |
| ▸ | ITGAV | P06756 | 20/20 | 0.77 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.68 |
| ▸ | ITGB5 | P18084 | 11/20 | 0.64 |
| ▸ | ITGB6 | P18564 | 10/20 | 0.64 |
| ▸ | ITGB8 | P26012 | 10/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21329747 | 1.00 | ITGB3 (0.77) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL6792186 | 0.99 | ITGB3 (0.76) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL15397316 | 0.99 | ITGB3 (0.79) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL6422102 | 0.97 | ITGB3 (0.77) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL20487381 | 0.97 | ITGB3 (0.77) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL6425719 | 0.97 | ITGB3 (0.77) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL5252527 | 0.95 | ITGB3 (0.73) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL6262063 | 0.95 | ITGB3 (0.74) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL6424214 | 0.94 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| Hydrochloric Acid SCHEMBL29416400 | 0.94 | ITGB3 (0.72) | ITGB3ITGAVITGA2BITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112689507-B | Amino acid compounds having unbranched linkers and methods of use thereof | 普利安特治疗公司 | 2024-07-30 | — | — | CN | claimed |
| EP-1040098-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | claimed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | claimed |
| EP-1040098-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-10-04 | — | — | EP | claimed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | claimed |
| WO-1999031061-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-06-24 | — | — | WO | claimed |
| CN-118994152-A | Integrin targeting ligands and uses thereof | 箭头药业股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-112074290-B | Integrin targeting ligands and uses thereof | 箭头药业股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-112689507-B | Amino acid compounds having unbranched linkers and methods of use thereof | 普利安特治疗公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-114929218-A | Treatment of liver diseases using integrin inhibitor combinations | 诺华股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| EP-3813818-A1 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| EP-1187592-A4 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6410526-B1 | BONE DISORDERS; RESTENOSIS; VISION DISORDERS; ANTICHOLESTEROL AGENTS; ANTICANCER, ANTITUMOR AGENTS | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1187592-A2 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | disclosed |
| US-6297249-B1 | SUBSTITUTED 2-CARBOXYALKYLPYRIDINES | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| WO-2000072801-A2 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396506-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | ITGB3 11/4885ITGAV 8/4885ITGA2B 1/4885 |
| US-20020010176-A1 | Integrin receptor antagonists | ITGAV, ITGB3, ADGRE5 | ITGB3 2/4885ITGAV 1/4885ITGA2B 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.